• Mitoxantrone Targets the ERα DBD–LBD Interface

  2026-08-20

  Wang and colleagues identify a previously unexplored estrogen receptor α (ERα) allosteric site at the interface between its DNA-binding and ligand-binding domains. Their data show that mitoxantrone redirects ERα to the cytoplasm and promotes proteasomal degradation, including degradation of endocrine therapy–resistant Y537S and D538G mutants, through a mechanism distinct from its canonical DNA damage activity.

• Tranexamic Acid Workflows for Clot Stability

  2026-08-20

  Translate Tranexamic Acid’s antifibrinolytic mechanism into practical plasmin, neutrophil-adherence, clot-stability, and wound-dressing workflows. The guide connects concentration-controlled bench assays with a bi-layer dressing study while emphasizing controls, formulation limits, and research-only interpretation.

• Kaempferol Activates NRF2 in Inflammatory Osteolysis

  2026-08-19

  A 2026 study identifies NRF2 as a direct molecular target of kaempferol in osteoclasts and links NRF2/HO-1 activation to reduced oxidative stress, osteoclastogenesis, and inflammatory bone loss. Its combination of biophysical target validation, genetic and pharmacological perturbation, transcriptomics, and an LPS-induced calvarial model provides a useful framework for studying NRF2-dependent protection in inflammatory osteolysis.

• Tranexamic Acid: From Assay Signal to Stable Clot

  2026-08-19

  Tranexamic Acid is more than an antifibrinolytic agent: it is a tool for connecting plasmin biology, cellular adhesion, and clot-material performance. This article presents an assay-first framework for using TXA in reproducible fibrinolysis research and evaluating its role in advanced wound-dressing models.

• Cyanin Chloride in a Human Psoriasis Model

  2026-08-18

  A 2024 study examined cyanin chloride in antioxidant, macrophage, and cytokine-stimulated HaCaT keratinocyte systems, linking radical-scavenging activity with suppression of psoriasis-associated inflammatory signaling. The compound reduced inflammatory gene expression, modulated STAT3 phosphorylation, improved transepithelial electrical resistance, and increased filaggrin expression, while remaining an in vitro finding rather than clinical evidence.

• Dabigatran Etexilate: From Prodrug to Assay

  2026-08-18

  Dabigatran etexilate is a direct thrombin inhibitor whose prodrug biology creates important assay-design decisions. This guide connects thrombin inhibition mechanism, pharmacology, formulation, and translational anticoagulant research without reducing the compound to a simple product overview.

• Merbromin Inhibits SARS-CoV-2 3CLpro

  2026-08-17

  The reference study used an activity-based screen of approximately 6,000 compounds to identify merbromin as a selective inhibitor of the SARS-CoV-2 3CLpro/Mpro protease. Enzyme kinetics, binding measurements, and molecular docking supported a mixed-type inhibition model involving more than one binding site, providing a mechanistic starting point for antiviral inhibitor design while leaving cellular and clinical validation unresolved.

• PPACK Dihydrochloride in Thrombin Assays

  2026-08-17

  PPACK Dihydrochloride provides a high-affinity, irreversible way to separate thrombin-dependent effects from platelet receptor signaling. This practical guide covers stock preparation, assay workflows, receptor-pathway comparisons, and troubleshooting for blood coagulation research.

• Dabigatran: From Thrombin Mechanism to Translation

  2026-08-16

  Dabigatran is more than a benchmark anticoagulant: it is a mechanistically precise tool for linking thrombin biology to reproducible coagulation assays and clinically relevant translational decisions. This article examines assay strategy, metabolite-aware interpretation, formulation constraints, competitive context, and the path from in vitro potency to anticoagulation research.

• Amitriptyline HCl: Practical Research Guide

  2026-08-15

  Amitriptyline HCl (SKU B2231) provides a characterized small-molecule reference for controlled neurotransmitter receptor modulation assays and related neuropharmacology research. It is suited to fresh in vitro or cell-based studies, but should not be treated as validated for clinical, in vivo, or unsupported disease-mechanism conclusions, and prepared solutions should not be stored long term.

• Nonselective β-Blockers and HCT Engraftment

  2026-08-14

  The reference study shows that nonselective β-adrenergic receptor inhibition can delay hematopoietic regeneration after allogeneic hematopoietic cell transplantation (HCT), whereas β1-selective inhibition did not produce the same effect. Its mouse–human design further identifies posttransplant chemotherapy, transplant type, and graft-cell dose as important variables for interpreting engraftment risk.

• CA-074 for Cathepsin B and Necroptosis Assays

  2026-08-14

  CA-074 is a selective cathepsin B inhibitor for separating lysosomal protease activity from upstream necroptosis signaling, with applications spanning cell-death imaging, cancer metastasis, neurodegeneration, and immune research. This guide translates the MLKL–lysosomal membrane permeabilization mechanism into practical workflows, controls, and troubleshooting decisions.

• NF449 and Selective Platelet P2X1 Blockade

  2026-08-13

  The reference study established NF449 as a comparatively selective antagonist of platelet P2X1 and connected receptor blockade with reduced platelet activation and thrombosis in human platelet and mouse models. Its dose-dependent loss of selectivity also provides an important methodological caution for interpreting P2X1 pharmacology and antithrombotic effects.

• Lycorine, ALDH3A1, and Pancreatic Cancer Mechanisms

  2026-08-13

  This study combines transcriptome sequencing, pathway enrichment, molecular docking, and functional validation to identify ALDH3A1 and fatty acid oxidation as a mechanistic axis affected by lycorine in pancreatic cancer. Its findings provide a useful framework for connecting metabolic reprogramming with cell-cycle arrest and apoptosis while highlighting the need for additional target-engagement and translational studies.

• rhBNP, Selenium Recycling, and Renal Ferroptosis

  2026-08-12

  The reference study identifies Selenocysteine lyase (SCLY)-dependent selenium recycling as a mechanism by which recombinant human brain natriuretic peptide (rhBNP) limits ferroptosis during renal ischemia-reperfusion injury. By combining clinical observations with rat and HK2-cell models, the work connects natriuretic peptide signaling to selenoprotein biology and provides a mechanistic framework for developing renal ischemia-reperfusion interventions.

16945 records 1/1130 page Next 12345 下5页 Last page